EP1397688A2 - Procede pour identifier des interactions entre des proteines et des fragments d'adn d'un genome - Google Patents
Procede pour identifier des interactions entre des proteines et des fragments d'adn d'un genomeInfo
- Publication number
- EP1397688A2 EP1397688A2 EP02754655A EP02754655A EP1397688A2 EP 1397688 A2 EP1397688 A2 EP 1397688A2 EP 02754655 A EP02754655 A EP 02754655A EP 02754655 A EP02754655 A EP 02754655A EP 1397688 A2 EP1397688 A2 EP 1397688A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- dna
- protein
- dna fragments
- library
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 83
- 239000012634 fragment Substances 0.000 title claims abstract description 39
- 230000006916 protein interaction Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 96
- 108020004414 DNA Proteins 0.000 claims abstract description 88
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 73
- 238000000338 in vitro Methods 0.000 claims abstract description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 4
- 230000003993 interaction Effects 0.000 claims description 18
- 239000011159 matrix material Substances 0.000 claims description 15
- 230000001105 regulatory effect Effects 0.000 claims description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000011521 glass Substances 0.000 claims description 9
- 238000011534 incubation Methods 0.000 claims description 9
- 239000013612 plasmid Substances 0.000 claims description 8
- 230000002285 radioactive effect Effects 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 7
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 7
- 241000206602 Eukaryota Species 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 230000004568 DNA-binding Effects 0.000 claims description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052737 gold Inorganic materials 0.000 claims description 5
- 239000010931 gold Substances 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- XSYUPRQVAHJETO-WPMUBMLPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidaz Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XSYUPRQVAHJETO-WPMUBMLPSA-N 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 150000001299 aldehydes Chemical class 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 238000007306 functionalization reaction Methods 0.000 claims description 2
- 230000009897 systematic effect Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 description 25
- 238000009739 binding Methods 0.000 description 21
- 230000027455 binding Effects 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 17
- 150000007523 nucleic acids Chemical class 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 12
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000007850 fluorescent dye Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102000034356 gene-regulatory proteins Human genes 0.000 description 6
- 108091006104 gene-regulatory proteins Proteins 0.000 description 6
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 101710096438 DNA-binding protein Proteins 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 239000011616 biotin Chemical group 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000003498 protein array Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical group CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000011898 label-free detection Methods 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 102100039502 E3 ubiquitin-protein ligase RNF34 Human genes 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 101001103581 Homo sapiens E3 ubiquitin-protein ligase RNF34 Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000863434 Myxococcales Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003380 quartz crystal microbalance Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
Definitions
- the present invention relates to a novel method for the parallel zn-vitro identification of DNA-protein changes effects, ie potential DNA binding sites for proteins of unknown function can be found in the genome of organisms.
- the proteins to be examined are incubated with DNA fragments that map the entire genome and then the sequences to which a specific binding takes place are identified.
- the DNA fragments are preferably used in immobilized form and the binding of the protein to be examined is detected.
- Upstream regulatory elements in front of genes and operons that are bound by DNA-binding proteins such.
- B. transcription factors can be identified, can be identified.
- the clarification of regulatory networks in complex biological systems is simplified and accelerated.
- this invention can be used in order to describe the function and networking of regulons and modulons in bacterial systems.
- DNA-protein interactions can be detected either in vivo, in vitro or by a combination of both experimental systems. As a rule, the investigations must be limited to one or only a few interacting and previously identified DNA-protein binding partners. By linking a so-called in vivo footprint with in vitro DNA microarray analyzes, even complex DNA mixtures can be checked for interactions based on a known or suspected DNA binding protein.
- In vivo analyzes determine the effect of a DNA binding protein in connection with a possible DNA binding site on the transcription rate of a gene located in ice downstream.
- the mRNA formed is detected and possibly quantified by z.
- the mRNA is radioactively marked during the in vivo transcription or the mRNA is subsequently hybridized with radioactive or fluorescence-labeled probes.
- the transcription rate can be indirectly correlated with the amount of the protein translated by this mRNA or with the enzyme activity derived therefrom.
- the DNA partner is usually radioactively marked.
- Protein and DNA are incubated in solution under various conditions and then either paired with a nitrocellulose membrane (filter binding) or immunoprecipitated with an antibody (McCay assay).
- McCay assay Another go The common method is the gel retardation assay, in which the electrophoretic running behavior of protein-bound DNA is compared with that of unbound DNA. Different incubation conditions such as salt concentration, pH value, competitor DNA etc. allow conclusions to be drawn about the specificity and binding constants between the protein and the DNA fragment.
- Chromatin immunoprecipitation with subsequent DNA microarray hybridization is based on the covalent linkage of DNA with cellular proteins catalyzed by formaldehyde or glutaraldehyde in an intact cell system. Because of their proximity, DNA binding proteins are preferentially bound to the DNA.
- the DNA from the cells treated in this way is extracted, fragmented (eg by scissors) and then immunoprecipitated using an antibody directed against the DNA binding protein to be examined.
- the DNA After separation of the DNA binding protein, the DNA can be amplified, labeled and hybridized against DNA spotted on microarrays. Compared to a control, e.g. B. a deletion mutant relating to the protein to be examined, specifically bound DNA fragments can be identified in parallel.
- the detection limit of this method is directly dependent on the presence or the amount of the regulatory protein to be examined, the intracellular concentration of which is generally very low.
- Nucleic acids are polymers and therefore bind to suitable carrier materials such as e.g. Membranes.
- Nucleic acids are always negatively charged due to the phosphate residues of the nucleotides. Accordingly, they can be transferred to positive carrier surfaces using purely electrostatic forces. tie surfaces. This is exploited when using supports that are functionalized with amino groups (eg polylysine-coated supports or supports modified with aminopropyltriethoxysilane (APTS)), or membranes with positively charged side groups. Both methods (pure adsorption or adsorption supported by electrostatic forces) are characterized by the fact that they are easy to carry out, since the simple incubation of the support with the nucleic acid is sufficient for coupling, and that they largely retain the functionality of the bound molecules , since they do not need any further manipulation of the biomolecules.
- APTS aminopropyltriethoxysilane
- nucleic acids have a phosphate group at their 5 'end. This can be activated (eg by carbodiimides and succinimides) so that chemical coupling to amino groups can take place.
- modified nucleic acids in particular nucleic acids which have an amino group or a biotin residue at one end.
- nucleic acids oligonucleotides
- Such nucleic acids are commercially available and can be incorporated into the nucleic acid to be investigated via polymerase reactions.
- Amino-functionalized nucleic acids bind quickly to aldehyde-modified supports (formation of Schiff bases), which are also commercially available as glass supports.
- they can be coupled to epoxy-functionalized carriers (modification, for example by means of suitable silanizing reagents) or else to carriers with carboxyl groups (after activation with carbodiimide and succinimd).
- the use of biotinylated nucleic acid allows stable coupling to avidin or streptavidin modified carriers.
- the coupling via reactions of the amino groups with aldehyde groups or via biotin (strept) avidin takes place so quickly that they are also suitable for the production of arrays with spotters.
- nucleic acids or proteins, for example avidin or streptavidin
- suitable functional groups for example amino, aldehyde, epoxy, carboxyl groups.
- such carriers are commercially available, in others these modifications must be carried out by yourself, which is usually done by reaction of the carrier with suitable silanizing reagents. No further requirements are placed on the carrier, so that planar glass carriers can be silanized just like glass beads or metallic carriers.
- carrier surfaces are often described in order to suppress non-specific interactions of later added molecules with the carrier.
- Such further modifications include the saturation of carrier surfaces with inert proteins, such as bovine serum albumin, but also the coating with polymers, such as dextrans, or polyacrylamide gel, which can also serve as the basis for the immobilization and thus increase the loading capacity of the surface.
- the immobilization principles described above can also be used for proteins, since proteins have sufficient functional groups, in particular for covalent couplings, due to the side groups of the amino acids. Since the charge of proteins is not as uniform as that of nucleic acids, immobilization due to electrostatic interactions is not as important, but pure adsorption reactions, which also include hydrophobic interactions, often lead to stable protein layers.
- the marking the binding properties of the protein are not changed.
- the coupling of the fluorescent dye in the region of the binding site of the protein could prevent the binding, or the coupling of highly hydrophobic dyes can lead to additional non-specific hydrophobic interactions with a carrier surface.
- markers radioisotopes, fluorescent dyes
- detection via subsequent reactions of the markers is also known.
- Enzymes whose reaction products are detected principle of enzyme immunoassays) or labels for which binding partners exist (eg biotin with streptavidin peroxidase and enzymatic reaction; digoxigenin with enzyme-labeled antibody and subsequent enzymatic reaction; His.) are also used as markers 6 with appropriate antibody).
- markers are suitable for the detection of bound nucleic acids as well as for the detection of bound proteins.
- the most elegant detection methods are based on the direct, label-free detection of an affinity reaction. They not only allow the detection of the binding of an unmodified binding partner, but also the quantification of this binding and the monitoring of the binding reaction in real time and thus the determination of kinetic constants, ie the association and dissociation constants. These methods are essentially based on the fact that the binding reaction to a partner immobilized on a support changes the mass coverage of this support or / and the thickness of the layers on this support. The change in the layer thickness can be tracked using interferometric, ie optical methods (RIFs principle).
- arrays have mainly been used for the detection of DNA-DNA interactions (expression analysis or sequencing with gene chips). Due to the need to elucidate the functions of the proteins encoded by the genes, the development of protein arrays is becoming more important. This is primarily about the detection of proteins by specific antibodies or similar binding proteins (protein A / G; receptors), or of enzyme activities. DNA-protein interactions with DNA fragments immobilized in array format have not yet been described. However, there are publications on the detection of DNA-protein interactions.
- the present invention enables a function assignment of proteins or genes whose biological function is hitherto unknown or only partially known.
- this invention enables a comprehensive, parallel in vitro identification of DNA-protein interactions and is independent of the expression of the regulatory protein to be examined in the actual host. This makes it possible, unaffected by environmental conditions, to clarify global regulatory networks in organisms in order to test them for their suitability for use in modulating metabolic pathways. Subsequent "genetic engineering” allows the optimization of, for example, fermentation processes for the production of enzymes, chemicals and pharmaceutically usable substances.
- the regulatory networks discovered on the basis of this invention can be used to identify new "drug targets" for the treatment of diseases in humans, animals and plants.
- the object on which the invention is based is thus achieved by a method for identifying interactions between proteins and DNA fragments of a genome, in which at least one protein is incubated with at least one DNA fragment of a genome in vitro and then the protein and / or DNA - Identified sequences that have interacted.
- the DNA fragments can map the genome of a procaryte or eukaryote, in particular a bacterium, a yeast or a fungus.
- a procaryte or eukaryote in particular a bacterium, a yeast or a fungus.
- DNA fragments which are present as a DNA vector library in particular as a DNA plasmid library.
- the DNA vector library with Escherichia coli clones can be provided.
- the DNA fragments can be arranged as a DNA library or as a DNA vector library in microtiter plates.
- the DNA fragments can be arranged multiple times in duplicate.
- the vector DNA of the library can be double-stranded and immobilized on a solid matrix.
- the vector DNA can be provided in an orderly or systematic manner.
- a solid, optionally functionalized support which is a glass support, a membrane or a gel, can be provided as the solid matrix.
- a functionalization of the support can be provided for the method according to the invention, which can couple the immobilized DNA fragments, in particular can bind covalently or electrostatically.
- the optionally functionalized support can be provided on a planar support element, in a column or in or on a capillary.
- a protein which is derived from the genome shown can also be used in the method according to the invention.
- the derived protein may have been heterologously expressed in a prokaryotic, in particular a bacterial, or in a eukaryoiitic expression system.
- a prokaryotic in particular a bacterial
- a eukaryoiitic expression system in particular a prokaryotic, in particular a bacterial, or in a eukaryoiitic expression system.
- the derived protein may have been expressed with an artificial epitope tag, in particular a histidine hexapeptide as an epitope tag.
- the incubation can be carried out simultaneously on all immobilized DNA fragments batchwise or in the flow.
- the incubation can also be carried out sequentially, in particular when immobilized in a column or in or on a capillary.
- the interacting partners, DNA fragment and protein can be covalently linked to one another, in particular using an aldehyde, preferably formaldehyde or glutaraldehyde.
- the interacting protein can be detected by looking at the protein
- the DNA fragments can have a size of 1.5 to 2.5 kB, 1.0 to 2.0 kB, 0.5 to 1.5 kB, 0.3 to 0.8 kB or 0.03 to 0.5 kB ,
- the method according to the invention can be carried out to identify DNA-protein interactions in complex DNA fragment mixtures, in particular to identify DNA binding sites for proteins of known or unknown function.
- the method according to the invention for identifying cis-arranged regulatory elements for the transcription of eukaryotic or prokaryotic genes can be carried out.
- the method according to the invention can be carried out for the function assignment of genes and / or proteins which are related to gene regulation, in particular for the identification of transcription factors or of genes which are regulated by transcription factors.
- the method according to the invention for elucidating regulatory networks in complex biological systems can be carried out, in particular for optimizing the cultivation of prokaryotes or eukaryotes on the basis of regulatory networks.
- the method according to the invention for optimizing fermentation processes can be carried out with the help of prokaryotes or eukaryotes on the basis of regulatory networks.
- the method according to the invention for identifying targets for the development of active substances or of methods for the treatment of diseases can be carried out.
- Another embodiment of the invention relates to a microtiter plate with a DNA library or DNA vector library arranged therein for carrying out the method according to the invention.
- Another embodiment of the invention relates to a solid matrix according to the invention with DNA fragments immobilized on the matrix.
- Another embodiment of the invention relates to a planar support element according to the invention with a solid matrix according to the invention applied thereon.
- the plasmid DNA of the library is immobilized in an orderly manner as a double strand 'on a solid matrix.
- a treated / coated glass surface, a membrane or a gel of different materials can be used as the matrix.
- the treatment or coating of the glass surface can be carried out in order to permit the coupling of the DNA (covalent or electrostatic), to suppress unspecific bonds (see 5.), or to enable detection (coating with, for example, a gold layer for detection via surface plasmon resonance).
- Other supports than glass supports can also be used if other detection methods than optical are selected.
- only the “insert DNA” of the recombinant plasmids can be immobilized in a directional manner. B. done using the PCR.
- the matrix can be on a planar support, but also in a column or on the wall of a capillary.
- the protein to be examined is selected by computer-aided analysis of DNA and protein sequences that are already available, e.g. B. from fully or partially sequenced genomes.
- a comparison of the derived amino acid sequences of ORFs with protein databases can provide first indications of DNA binding proteins.
- the assignment of the derived proteins to so-called COGs (clusters of orthologous groups) or the presence of special structural motifs (eg “helix-turn-helix” motifs) can make it possible to predict a potential DNA-binding activity.
- the gene / gene product selected under 3) is heterologously expressed in a bacterial or eukaryotic expression system with or without an artificial “epitope tag (eg histidine hexapeptide) and then purified in its native state.
- an artificial “epitope tag eg histidine hexapeptide
- the protein present in buffer solution is incubated with the double-stranded DNA immobilized on a matrix. Non-specific interactions of the protein with the matrix or the DNA are suppressed by suitable surface treatments or washing steps, or made visible by competition experiments.
- the incubation can be carried out simultaneously on all immobilized DNA samples in batch or in flow, or sequentially (preferably when the DNA is immobilized in columns or capillaries and corresponding flow systems).
- the interacting partners are covalently linked to one another using crosslinkers (for example formaldehyde or glutaraldehyde).
- crosslinkers for example formaldehyde or glutaraldehyde.
- the detection of the regulator protein is then carried out by means of immunological methods using (enzyme, fluorescence or radioactive) labeled antibodies which are directed against the regulator protein or the "epitope tag" present on the regulator protein. Detection methods are used which allow a label-free measurement (eg surface plasmon resonance; "resonant mirror”;interferometer; piezocrystals), the attachment of the protein can be followed directly without the need for antibodies.
- the method described above identifies protein-DNA binding partners with the aid of a heterologously expressed protein and a DNA library.
- the ordered plasmid library allows the clear assignment to genomic DNA regions of the organism to be examined.
- the sequencing of the "inserts" of the plasmids filtered out makes it possible to identify the genes which are in the immediate vicinity of the protein binding region. In the case of fully sequenced genomes, DNA sequences which influence the regulation of genes and operons can be identified in this way.
- the biochemical and biological characterization of the DNA-protein interactions can then be carried out using various "state-of-the-art" methods (for example, by sequence comparison, marker gene analysis in combination with deletion studies, DNAse protection analysis, reporter gene analysis, etc.).
- LexA modulates the expression of many regulons of the SOS system.
- TyrA controls 8 operons bifunctionally as a repressor and activator.
- FnrR is involved in the regulation of more than 30 transcription units.
- LrpR affects the transcription of 8 operons.
- PhoPQ is involved in the regulation of at least 7 operons.
- DNA chips a) Nature Genet. 21 (1999) Suppl. B) K. Niikura, K. Nagata, Y. Okahata, Quantitative detection of protein binding onto DNA by using a quartz-crystal microbalance, Chem. Lett. 1996, 863-4 c) D. Guschin, G. Yershov, A. Zaslavsky, A. Gemmell, V. Shick, D. Proudnikov, P. Arenkov, A. Mirzabekov, Manual Manufacturing of oligonucleotides, DNA, and protein microchips, Anal. Biochem. 250, 1997, 203-11
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
L'invention concerne un procédé pour identifier des interactions entre des protéines et des fragments d'ADN d'un génome, consistant à incuber in vitro au moins une protéine avec au moins un fragment d'ADN d'un génome, puis à identifier les séquences de protéine et/ou d'ADN qui sont entrées en interaction.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10128321 | 2001-06-12 | ||
DE10128321A DE10128321A1 (de) | 2001-06-12 | 2001-06-12 | Verfahren zur Identifizierung von Wechselwirkungen zwischen Proteinen und DNA-Fragmenten eines Genoms |
PCT/EP2002/006406 WO2002101393A2 (fr) | 2001-06-12 | 2002-06-11 | Procede pour identifier des interactions entre des proteines et des fragments d'adn d'un genome |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1397688A2 true EP1397688A2 (fr) | 2004-03-17 |
Family
ID=7687934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02754655A Withdrawn EP1397688A2 (fr) | 2001-06-12 | 2002-06-11 | Procede pour identifier des interactions entre des proteines et des fragments d'adn d'un genome |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040209267A1 (fr) |
EP (1) | EP1397688A2 (fr) |
AU (1) | AU2002320845A1 (fr) |
DE (1) | DE10128321A1 (fr) |
WO (1) | WO2002101393A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070154906A1 (en) * | 2005-10-05 | 2007-07-05 | Spirogen Ltd. | Methods to identify therapeutic candidates |
US20080248958A1 (en) * | 2007-04-05 | 2008-10-09 | Hollenbach Andrew D | System for pulling out regulatory elements in vitro |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5700637A (en) * | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5556752A (en) * | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US6669906B1 (en) * | 1997-04-22 | 2003-12-30 | Thomas Schalkhammer | Reinforced cluster optical sensors |
WO1999000520A1 (fr) * | 1997-06-30 | 1999-01-07 | The Government Of The United States Of America, Reresented By The Secretary Of The Department Of Health And Human Services | Le clonage spectral - une nouvelle approche technique du clonage et caracterisation de toutes les aberrations chromosomiques dans des echantillons cancereux |
US20020025552A1 (en) * | 1998-01-06 | 2002-02-28 | Institut Pasteur | Screening interactor molecules with whole genome oligonucleotide or polynucleotide arrays |
WO2000053813A1 (fr) * | 1999-03-11 | 2000-09-14 | Massachusetts Institute Of Technology | Bibliotheques pangenomiques |
WO2002086095A2 (fr) * | 2001-04-23 | 2002-10-31 | Chou Michael F | Methodes permettant de decouvrir un reseau de facteurs de transcription |
-
2001
- 2001-06-12 DE DE10128321A patent/DE10128321A1/de not_active Withdrawn
-
2002
- 2002-06-11 WO PCT/EP2002/006406 patent/WO2002101393A2/fr not_active Application Discontinuation
- 2002-06-11 US US10/480,713 patent/US20040209267A1/en not_active Abandoned
- 2002-06-11 EP EP02754655A patent/EP1397688A2/fr not_active Withdrawn
- 2002-06-11 AU AU2002320845A patent/AU2002320845A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO02101393A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002320845A1 (en) | 2002-12-23 |
WO2002101393A3 (fr) | 2003-11-06 |
US20040209267A1 (en) | 2004-10-21 |
DE10128321A1 (de) | 2003-01-02 |
WO2002101393A2 (fr) | 2002-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60120713T2 (de) | Funktionelles protein array | |
Kumar et al. | Emerging technologies in yeast genomics | |
US7771940B2 (en) | Methods of detecting a plurality of sequence specific DNA binding proteins with oligonucleotide detection duplexes | |
EP1135527B1 (fr) | Clonage et copie sur des surfaces | |
Choudhuri | Microarrays in biology and medicine | |
DE10155600B4 (de) | Nukleinsäure-Array | |
JP2002531852A (ja) | 胚様体を用いる毒性の分類 | |
DE60111927T2 (de) | Methode und kit zum auffinden, zum nachweis und/oder zur quantifizierung von transkriptionsfaktoren | |
US20090018025A1 (en) | Testing Method of Nucleic Acid Binding Protein Based on Biochip | |
EP1397688A2 (fr) | Procede pour identifier des interactions entre des proteines et des fragments d'adn d'un genome | |
DE60221964T2 (de) | Verfahren und testkit zur quantitativen bestimmung von variationen der polynukleotidmengen in zell- oder gewebeproben | |
DE112004002318T5 (de) | Transkriptionsregulatoren und Verfahren dazu | |
CA2220785A1 (fr) | Technique selective d'identification rapide des proteines et des genes et usages pertinents | |
DE19902391A1 (de) | Verfahren zur reversiblen, ortsspezifischen, hocheffizienten und gleichzeitigen Immobilisierung verschiedenartiger (biologischer) Makromoleküle auf Festphasen | |
DE19923966C2 (de) | Erkennungssystem zur Auftrennung von Probenbestandteilen, seine Herstellung und Verwendung | |
DE112004002217B4 (de) | Proteinbildungskomplex mit einem c-Jun-Protein, Nucleinsäure, codierend denselben und Verfahren unter Verwendung desselben | |
Li et al. | Genome-wide in vivo cross-linking of sequence-specific transcription factors | |
DE60209273T2 (de) | Chip aus biologischen Materialien | |
WO2005028671A2 (fr) | Procede pour determiner des marqueurs de cycle capillaire | |
Jordan | The microarray paradigm and its various implementations | |
EP2217364A2 (fr) | Procédé d'extraction flexible permettant la production de bibliothèques de molécules spécifiques d'une séquence | |
WO2003058240A2 (fr) | Procédé de détection comparative qualitative et quantitative de substances chimiques | |
DE10164197A1 (de) | Steuerbare Verstärkung der Empfindlichkeit beim Hybridisierungsnachweis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17P | Request for examination filed |
Effective date: 20031215 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20041116 |